Lovenox is the low molecular weight heparin manufactured by the world renowned formulators known as Sanofi-Aventis. The drug contains the most effective ingredient called Enoxaparin. Lovenox is the Enoxaparin sodium injection – the unique chemical entity from the class of anti-thrombotic agent known as low molecular weight heparins – LMWH. Lovenox or Enoxaparin is used for preventing and treating the deep vein thrombosis which are the blood clots that may form in the legs then moving further to the lungs where it may turn to be fatal or pulmonary embolism and is usually administered as the subcutaneous injection by the healthcare providers. The use of Lovenox or Enoxaparin is evolving in the acute coronary syndromes.

Lovenox has been approved in the United States and Canada since 1993 and it’s been available in Europe since 1987. Lovenox is the only LWMH in the United States approved by the Food and Drugs Administration for 7 approved indications for the prophylaxis and treatments of Thrombo-embolic diseases. Lovenox has been trusted for its safety and efficacy for over 15 years treating more than 100 million patients in around 96 countries of the world. Lovenox may protect you from the risk of Deep Vein Thrombosis which is the blood clotting that could form in the legs. The clinical trial results of Lovenox has exhibited 99% efficacy in protecting hospitalized patients from the DVT blood clotting.

It is an anticoagulant which thins the blood and modifies regular blood clotting system. Lovenox could easily be taken in combination with other drugs since it has very few side effects, and it is required to be administered just once or twice daily. The drug could also be given to the patient who already has blood clots in the body. The length of treatment or the course of typical treatment with Lovenox can be determined by your doctor based on your individual illness status.